医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
22期
130-132
,共3页
刘城%吴平生%王月刚%裴静娴%赖艳娴
劉城%吳平生%王月剛%裴靜嫻%賴豔嫻
류성%오평생%왕월강%배정한%뢰염한
姜黄素%人微血管内皮细胞%肿瘤性血管新生%抑制
薑黃素%人微血管內皮細胞%腫瘤性血管新生%抑製
강황소%인미혈관내피세포%종류성혈관신생%억제
Curcumin(Cur)%Human microvascular endothelial cell(HMVEC-Ls)%Tumor angiogenesis%Inhibition
目的研究姜黄素在人微血管内皮细胞增殖、迁移、成管以及凋亡的作用,并初步探讨其机制。方法将姜黄素分为0、20、40及80μmol/L四个实验组,分别用MTS 法、划痕实验、成管实验以及Hoechst 33258与TUNEL双重荧光检测姜黄素对人微血管内皮细胞增殖细胞增殖、迁移、成管以及凋亡的影响。结果 MTS结果显示:从姜黄素与HMVEC-Ls共同培养的第1d开始,(20-80)μmol/L三个浓度组均可抑制HMVEC-Ls增殖,与对照组(0μg/mL)相比差异有显著性(p<0.05),尤以80μmol/L组抑制HMVEC-Ls增殖能力最显著(p<0.05)。划痕实验结果显示:(0-80)μmol/L四个姜黄素浓度组HMVEC-Ls迁移率分别为(92.33±5.01)%、(82.50±5.09)%、(63.00±5.73)%及(41.00±4.15)%,各实验组HMVEC-Ls迁移率差异有显著性(P<0.05),其中尤以80μmol/L组HMVEC-Ls迁移率最低。成管实验。结果(0-80)μmol/L四个姜黄素浓度组HMVEC-Ls成管长度分别为(2.76±0.14)、(1.76±0.09)、(0.90±0.16)、(0.34±0.07)mm/视野,各实验组HMVEC-Ls成管长度差异有显著性(P<0.05),其中尤以80μmol/L组HMVEC-Ls成管长度最小。Hoechst33258与TUNEL双重荧光染色。结果在姜黄素与HMVEC-Ls共同培养过程中HMVEC-Ls发生了凋亡。结论姜黄素可通过抑制人微血管内皮细胞增殖、迁移、管样形成并诱导其发生凋亡从而有效抑制肿瘤血管形成,是一种非常具有临床应用前景的抗肿瘤药物。
目的研究薑黃素在人微血管內皮細胞增殖、遷移、成管以及凋亡的作用,併初步探討其機製。方法將薑黃素分為0、20、40及80μmol/L四箇實驗組,分彆用MTS 法、劃痕實驗、成管實驗以及Hoechst 33258與TUNEL雙重熒光檢測薑黃素對人微血管內皮細胞增殖細胞增殖、遷移、成管以及凋亡的影響。結果 MTS結果顯示:從薑黃素與HMVEC-Ls共同培養的第1d開始,(20-80)μmol/L三箇濃度組均可抑製HMVEC-Ls增殖,與對照組(0μg/mL)相比差異有顯著性(p<0.05),尤以80μmol/L組抑製HMVEC-Ls增殖能力最顯著(p<0.05)。劃痕實驗結果顯示:(0-80)μmol/L四箇薑黃素濃度組HMVEC-Ls遷移率分彆為(92.33±5.01)%、(82.50±5.09)%、(63.00±5.73)%及(41.00±4.15)%,各實驗組HMVEC-Ls遷移率差異有顯著性(P<0.05),其中尤以80μmol/L組HMVEC-Ls遷移率最低。成管實驗。結果(0-80)μmol/L四箇薑黃素濃度組HMVEC-Ls成管長度分彆為(2.76±0.14)、(1.76±0.09)、(0.90±0.16)、(0.34±0.07)mm/視野,各實驗組HMVEC-Ls成管長度差異有顯著性(P<0.05),其中尤以80μmol/L組HMVEC-Ls成管長度最小。Hoechst33258與TUNEL雙重熒光染色。結果在薑黃素與HMVEC-Ls共同培養過程中HMVEC-Ls髮生瞭凋亡。結論薑黃素可通過抑製人微血管內皮細胞增殖、遷移、管樣形成併誘導其髮生凋亡從而有效抑製腫瘤血管形成,是一種非常具有臨床應用前景的抗腫瘤藥物。
목적연구강황소재인미혈관내피세포증식、천이、성관이급조망적작용,병초보탐토기궤제。방법장강황소분위0、20、40급80μmol/L사개실험조,분별용MTS 법、화흔실험、성관실험이급Hoechst 33258여TUNEL쌍중형광검측강황소대인미혈관내피세포증식세포증식、천이、성관이급조망적영향。결과 MTS결과현시:종강황소여HMVEC-Ls공동배양적제1d개시,(20-80)μmol/L삼개농도조균가억제HMVEC-Ls증식,여대조조(0μg/mL)상비차이유현저성(p<0.05),우이80μmol/L조억제HMVEC-Ls증식능력최현저(p<0.05)。화흔실험결과현시:(0-80)μmol/L사개강황소농도조HMVEC-Ls천이솔분별위(92.33±5.01)%、(82.50±5.09)%、(63.00±5.73)%급(41.00±4.15)%,각실험조HMVEC-Ls천이솔차이유현저성(P<0.05),기중우이80μmol/L조HMVEC-Ls천이솔최저。성관실험。결과(0-80)μmol/L사개강황소농도조HMVEC-Ls성관장도분별위(2.76±0.14)、(1.76±0.09)、(0.90±0.16)、(0.34±0.07)mm/시야,각실험조HMVEC-Ls성관장도차이유현저성(P<0.05),기중우이80μmol/L조HMVEC-Ls성관장도최소。Hoechst33258여TUNEL쌍중형광염색。결과재강황소여HMVEC-Ls공동배양과정중HMVEC-Ls발생료조망。결론강황소가통과억제인미혈관내피세포증식、천이、관양형성병유도기발생조망종이유효억제종류혈관형성,시일충비상구유림상응용전경적항종류약물。
Objective: To study the effects of curcumin on human microvascular endothelial cel (HMVEC-Ls) proliferation, migration, tube formation and apoptosis in vitro. Method:The HMVEC-Ls were treated with different concentrations of curcumin (0, 20, 40 and 80 μmol/L), and HMVEC-Ls proliferation, migration, tube formation and apoptosis were then measured by MTS assay, wound-healing migration assay, Matrigel assay and Hoechst33258 /TUNEL costaining, respectively. Result: The HMVEC-Ls proliferation migration and tube formation was suppressed by curcumin treatment (P<0.05). In contrast, there were significant differences on HMVEC-Ls proliferation at the concentrations of 20, 40 and 80 μmol/L compared with the control group (0 μmol/L) (p<0.05).The HMVEC-Ls migration ratio among the 0, 20 , 40 and 80 μmol/L group were determined to be (92.33±5.01)%, (82.50±5.09)%, (63.00±5.73)%, and (41.00±4.15)%, respectively (p<0.05). Meanwhile, the tube length of HMVEC-Ls among the four experimental group were (2.76±0.14), (1.76±0.09), (0.90±0.16) and (0.34±0.07) mm/field, respectively (p<0.05). In addition, we found the characteristics of apoptosis treated with curcumin at the concentration 80μmol/L. by Hoechst33258 /TUNEL costaining. Conclusion: These findings suggest that curcumin may play pivotal roles in tumor angiogenesis suppression via the inhibition of HMVEC-Ls proliferation, migration, tube formation and promotion of apoptosis.